Federal Circuit Vacates PTAB Ruling on CRISPR-Cas9 Invention, Orders Reconsideration of Patent Priority
Appeals court finds Patent Trial and Appeal Board applied incorrect legal standards in CRISPR-Cas9 interference case involving Broad Institute and CVC
The U.S. Court of Appeals for the Federal Circuit has overturned the Patent Trial and Appeal Board’s 2022 decision awarding priority of CRISPR-Cas9 gene editing invention to the Broad Institute. The court ruled that the PTAB applied the wrong legal standard and failed to consider relevant evidence, remanding the case…